

# Superior efficacy in liver decline

Triple  
care  
solution<sup>1-6</sup>

Robust  
clinical  
evidence<sup>5,7,8</sup>

High  
source of  
DLPC

From the damaged hepatic cell...

## MEMBRANE RESTRUCTURATION

### INTEGRITY

More DLPC  
than in other EPLs<sup>9</sup>



DLPC

76%

of purified  
PPC<sup>9\*</sup>

72%

of PPC  
is the minimal  
amount to treat  
patients with  
NAFLD<sup>7</sup>

... to the fatty liver

## REVITALIZATION

INTEGRITY  
Ultrasonographic  
improvements<sup>10\*\*</sup>

2x  
more



### RESPONSIVENESS

Additional reduction  
in symptom  
incidence<sup>10\*\*</sup>



### FUNCTION

Greater  
AST & ALT  
reduction<sup>10\*\*\*</sup>

-22%



## RECOGNISED OPTION IN NAFLD

Recommended by  
*The Russian Society  
for the Study of the Liver*<sup>11</sup>

Rare and weak  
side effects<sup>8#</sup>

No toxic  
reactions reported<sup>8</sup>




>200  
clinical studies  
overall<sup>7</sup>

# Essentiale<sup>®</sup>

Triple care solution



Restores and maintains liver  
**responsiveness, integrity** and **function**



\*vs 29% in other EPLs; \*\*compared to UDCA after 12 weeks of treatment; \*\*\* vs 15% AST reduction and 20% ALT reduction with UDCA after 6 months; # compared to UDCA<sup>12,13</sup>, SAME<sup>14</sup>, silymarin<sup>15</sup>

DLPC: Dilinoleoylphosphatidylcholine; PPC: Phosphatidylcholine; EPL: Essential phospholipids; UDCA: Ursodeoxycholic acid; SAME: S-adenosyl Methionine.

1. Suicheng G. China Foreign Med J. 2008;6(3); 2. Gonciarz Z, et al. Med Chir Digest. 1988;17(1):61-65; 3. Sas E, et al. J Hepatol. 2013;58:S549-S566; 4. Sas E, et al. Gut. 2012;61(2):A216-A217; 5. Dajani A, et al. Arab J Gastroenterol. 2015;16:990-104; 6. Sun C, et al. Clinical Focus. 2008;23(17); 7. Gunderman K, et al. Pharmacol Rep. 2011;63:643-659; 8. Gundermann KJ, et al. Clin Exper Gastroenterol. 2016;9:105-117; 9. Vasilenko IA, et al. Gastroenterologija 2013;issue 13; 10. Arvind N, et al. Indian J Clin Pract. 2006;16:21-24; 11. The Russian Society for the Study of the Liver. Methodical recommendations for physicians/Edited by academic of the Russian Academy of Sciences, Professor V.T. Ivashkin "Diagnostics and treatment of non-alcoholic fatty liver disease", Moscow, 2015; 12. Instruction for medical use of Ursosan<sup>®</sup> medication, N000976, dated from 17.03.2016 in the Republic of Kazakhstan; 13. Ursosan<sup>®</sup>, New Zealand data sheet; 14. Instruction for medical use of Heptral<sup>®</sup> medication, N<sup>o</sup>779, dated from 18.09.2015; 15. Instruction for medical use of Hepabene<sup>®</sup> medication.13.02.2017.

SANOFI